David K. Henderson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
David K. Henderson has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
Tara N. Palmore
George Washington University School of Medicine and Health Sciences, Washington, DC (T.N.P.)
9 shared publicationsDavid J. Weber
University of North Carolina, Chapel Hill, North Carolina
4 shared publicationsA. Rekha Murthy
Cedars Sinai Health System, Los Angeles, California
3 shared publicationsAnurag Malani
St. Joseph Mercy Health System, Ann Arbor, Michigan
3 shared publicationsClare Rock
Johns Hopkins University School of Medicine, Baltimore, Maryland
3 shared publicationsFor The Shea Board Of Trustees
3 shared publications
Latest Publications
- Open Access
- 15 September 2025
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 46 (9) , 863-873
2025 US Public Health Service Guidelines for the Management of Occupational Exposures to Human Immunodeficiency Virus and Recommendations for Post-exposure Prophylaxis in Healthcare Settings
These guidelines update the 2013 “Updated US Public Health Service (PHS) Guidelines for the Management of Occupational Exposures to Human Immunodeficiency Virus and Recommendations for Postexposure Prophylaxis,” hereafter referred to as the 2013 PHS Guidelines. 1,2 The availability of new medication options, new information on the window of detection for different human immunodeficiency virus (HIV) tests, and the risk of transmission from people with undetectable viral loads prompted this update. The primary intended audience for these recommendations remains anyone involved in the provision of HIV post-exposure management to healthcare personnel (HCP). The U.S. Centers for Disease Control and Prevention assembled a working group of representatives from federal agencies in the U.S. Department of Health and Human Services (HHS) who identified the priority topics for update and conducted systematic literature reviews to formulate recommendations (see Appendix). All recommendations were reviewed by the Healthcare Infection Control Practices Advisory Committee (HICPAC) at public meetings, and by a non-consensus forming panel of external experts. New evidence-based recommendations are developed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework and classified according to the HICPAC recommendation scheme when evidence supported recommendation development. 3,4 Other recommendations in this document are classified as good practice statements according to the criteria set forth by GRADE. 5 The working group solicited additional feedback on recommendations from relevant agencies, subject-matter experts, and the public. Recommendations that have changed since the 2013 PHS guidelines include: new antiretroviral drug regimens for post-exposure prophylaxis (PEP); a shortened duration of post-exposure follow-up HIV testing; elimination of routine laboratory tests for antiretroviral drug toxicity; and considerations for PEP for HCP with exposures to source patients with undetectable viral loads. Important strategies in the principles of exposure management remain: primary prevention strategies; the prompt reporting and management of occupational exposures; adherence to recommended HIV PEP regimens when indicated; the role of expert consultation in management of exposures; and follow-up of exposed HCP.
- 15 September 2025
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 46 (9) , 863-873
Open Access2025 US Public Health Service Guidelines for the Management of Occupational Exposures to Human Immunodeficiency Virus and Recommendations for Post-exposure Prophylaxis in Healthcare Settings
These guidelines update the 2013 “Updated US Public Health Service (PHS) Guidelines for the Management of Occupational Exposures to Human Immunodeficiency Virus and Recommendations for Postexposure Prophylaxis,” hereafter referred to as the 2013 PHS Guidelines. 1,2 The availability of new medication options, new information on the window of detection for different human immunodeficiency virus (HIV) tests, and the risk of transmission from people with undetectable viral loads prompted this update. The primary intended audience for these recommendations remains anyone involved in the provision of HIV post-exposure management to healthcare personnel (HCP). The U.S. Centers for Disease Control and Prevention assembled a working group of representatives from federal agencies in the U.S. Department of Health and Human Services (HHS) who identified the priority topics for update and conducted systematic literature reviews to formulate recommendations (see Appendix). All recommendations were reviewed by the Healthcare Infection Control Practices Advisory Committee (HICPAC) at public meetings, and by a non-consensus forming panel of external experts. New evidence-based recommendations are developed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework and classified according to the HICPAC recommendation scheme when evidence supported recommendation development. 3,4 Other recommendations in this document are classified as good practice statements according to the criteria set forth by GRADE. 5 The working group solicited additional feedback on recommendations from relevant agencies, subject-matter experts, and the public. Recommendations that have changed since the 2013 PHS guidelines include: new antiretroviral drug regimens for post-exposure prophylaxis (PEP); a shortened duration of post-exposure follow-up HIV testing; elimination of routine laboratory tests for antiretroviral drug toxicity; and considerations for PEP for HCP with exposures to source patients with undetectable viral loads. Important strategies in the principles of exposure management remain: primary prevention strategies; the prompt reporting and management of occupational exposures; adherence to recommended HIV PEP regimens when indicated; the role of expert consultation in management of exposures; and follow-up of exposed HCP.
- 7 June 2024
- Published by Wolters Kluwer Health in Current Opinion in Infectious Diseases
- Vol. 37 (4) , 296-303
Postexposure prophylaxis for occupational exposure to selected pathogens for healthcare personnel
Purpose of review: Timely postexposure prophylaxis is important after an occupational exposure. Here we review select organisms, exposure opportunities in the healthcare setting, and postexposure prophylaxis regimens. Recent findings: Needlestick injuries pose a risk of exposure to bloodborne pathogens, such as HIV, Hepatitis B, and Hepatitis C. Risk mitigation strategies should be reexamined in light of newer vaccines and therapeutics. Increased vaccine hesitancy and vaccine denialisms may foster the re-emergence of some infections that have become extremely uncommon because of effective vaccines. With increasing occurrences of zoonotic infections and the ease of global spread as evidenced by COVID-19 and mpox, healthcare exposures must also consider risks related to emerging and re-emerging infectious diseases. Summary: Early recognition and reporting of occupational exposures to pathogens with available postexposure prophylaxis is key to mitigating the risk of transmission. Providers should be able to evaluate the exposure and associated risks to provide prompt and appropriate postexposure prophylaxis.
- 7 June 2024
- Published by Wolters Kluwer Health in Current Opinion in Infectious Diseases
- Vol. 37 (4) , 296-303
Postexposure prophylaxis for occupational exposure to selected pathogens for healthcare personnel
Purpose of review: Timely postexposure prophylaxis is important after an occupational exposure. Here we review select organisms, exposure opportunities in the healthcare setting, and postexposure prophylaxis regimens. Recent findings: Needlestick injuries pose a risk of exposure to bloodborne pathogens, such as HIV, Hepatitis B, and Hepatitis C. Risk mitigation strategies should be reexamined in light of newer vaccines and therapeutics. Increased vaccine hesitancy and vaccine denialisms may foster the re-emergence of some infections that have become extremely uncommon because of effective vaccines. With increasing occurrences of zoonotic infections and the ease of global spread as evidenced by COVID-19 and mpox, healthcare exposures must also consider risks related to emerging and re-emerging infectious diseases. Summary: Early recognition and reporting of occupational exposures to pathogens with available postexposure prophylaxis is key to mitigating the risk of transmission. Providers should be able to evaluate the exposure and associated risks to provide prompt and appropriate postexposure prophylaxis.
- Open Access
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
2464. Implementation of a Candida auris admission surveillance protocol at the NIH Clinical Center
Candida auris (C. auris) is a highly transmissible and usually multi-drug resistant yeast that causes serious invasive infections, with a high mortality rate, colonizes patients, and persists in the environment, resulting in outbreaks in healthcare settings. In 04/2019, The NIH Clinical Center (CC) identified a sensitive C. auris isolate from a blood culture. In 08/2019, the CC’s first case of resistant C. auris was identified from a patient recently hospitalized abroad. By the end of 2019, a total of 17 cases of C auris were identified in the state in which our institution resides (Maryland), as well as cases in institutions in the District of Columbia and Virginia (DMV). This led the CC to implement a C. auris admission surveillance program. From 11/2019 to 03/2023, nares, axilla, throat, and groin swabs (n=1408) were collected on admission from patients hospitalized: 1) abroad, 2) in long-term care facilities (LTAC), or 3) in the DMV within the last 6 months. 467 unique patients were tested, 315 by culture utilizing Sabouraud dulcitol broth containing 10% NaCl, Gentamicin, and Chloramphenicol, incubated at 40 degrees and Candida chrome incubated at 30 degrees. 152 patients were tested by PCR, utilizing E-swabs to collect axilla/ groin specimens and aluminum shafted culturette swabs for the nares. PCR testing was conducted at a reference lab from 10/2021 to 07/2022, while routine culturing was unavailable at our facility. Of 1408 cultures and PCRs collected on admission, no additional patients were identified with C. auris. C. auris surveillance is a vital strategy to identify colonized or infected patients. Despite the CC serving a large international patient population and patients hospitalized in facilities from states with a high prevalence of C. auris, our surveillance program has not identified additional positives. With cases steadily increasing across the United States (2022 – 2,377 clinical cases and 5,754 screening cases from 29 states) and because of the vulnerability of our patient population, we will continue screening. Tara Palmore, MD, Abbvie: Grant/Research Support|Gilead: Grant/Research Support|Rigel: Grant/Research Support
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
Open Access2464. Implementation of a Candida auris admission surveillance protocol at the NIH Clinical Center
Candida auris (C. auris) is a highly transmissible and usually multi-drug resistant yeast that causes serious invasive infections, with a high mortality rate, colonizes patients, and persists in the environment, resulting in outbreaks in healthcare settings. In 04/2019, The NIH Clinical Center (CC) identified a sensitive C. auris isolate from a blood culture. In 08/2019, the CC’s first case of resistant C. auris was identified from a patient recently hospitalized abroad. By the end of 2019, a total of 17 cases of C auris were identified in the state in which our institution resides (Maryland), as well as cases in institutions in the District of Columbia and Virginia (DMV). This led the CC to implement a C. auris admission surveillance program. From 11/2019 to 03/2023, nares, axilla, throat, and groin swabs (n=1408) were collected on admission from patients hospitalized: 1) abroad, 2) in long-term care facilities (LTAC), or 3) in the DMV within the last 6 months. 467 unique patients were tested, 315 by culture utilizing Sabouraud dulcitol broth containing 10% NaCl, Gentamicin, and Chloramphenicol, incubated at 40 degrees and Candida chrome incubated at 30 degrees. 152 patients were tested by PCR, utilizing E-swabs to collect axilla/ groin specimens and aluminum shafted culturette swabs for the nares. PCR testing was conducted at a reference lab from 10/2021 to 07/2022, while routine culturing was unavailable at our facility. Of 1408 cultures and PCRs collected on admission, no additional patients were identified with C. auris. C. auris surveillance is a vital strategy to identify colonized or infected patients. Despite the CC serving a large international patient population and patients hospitalized in facilities from states with a high prevalence of C. auris, our surveillance program has not identified additional positives. With cases steadily increasing across the United States (2022 – 2,377 clinical cases and 5,754 screening cases from 29 states) and because of the vulnerability of our patient population, we will continue screening. Tara Palmore, MD, Abbvie: Grant/Research Support|Gilead: Grant/Research Support|Rigel: Grant/Research Support
- Open Access
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
2475. Admissions Screening for Influenza and RSV Among a Highly Immunosuppressed Patient Population
During the Fall/Winter 2022-23, the U.S. experienced an early surge of Influenza and RSV cases, while SARS-CoV-2 cases persisted. With concerns of a potential “tripledemic” on the horizon, the NIH Clinical Center, a clinical research hospital with a heavily immunosuppressed patient population, implemented Influenza and RSV testing, in addition to SARS-CoV-2, for all patients on admission to facilitate early detection and prompt isolation of infected patients. Nasopharyngeal (NP) swabs (n=1213) were collected on admission from 11/2022 to 4/2023 and tested for Influenza and RSV by PCR. 1213 NP swabs from 985 unique patients were tested (some patients had multiple admissions); 1100 were tested on the Panther Fusion® SARS-CoV-2 Assay (Hologic, Inc.) and 113 using the SARS-CoV-2 RT-PCR Xpert® Xpress test. Medical chart reviews and discussions with patient care providers elucidated whether cases identified on admission were asymptomatic. Of 1213 NP swabs collected from patients admitted to our hospital, 5 (0.41%) were identified with Influenza A infection, 4 (0.33%) RSV infection and no patients were identified with Influenza B. Two (0.16%) had a known history of RSV infection, 3 (0.25%) screened negative for symptoms but subsequently disclosed symptoms, 1 (0.08%) was asymptomatic on admission but disclosed a recent history of an upper respiratory infection, and 3 were asymptomatic. All infections were detected between late November 2022 to mid-January 2023, when community transmission was high, yielding a 2-month positivity rate of 2.3% during this time of peak community spread. Admission surveillance for Influenza and RSV during a respiratory virus surge in our community allowed us to isolate nine patients on admission who would likely not have been appropriately isolated, as symptom screening alone is not reliable. Surveillance is important to be able to identify infected patients promptly when respiratory infections are rampant in the community, and especially for institutions serving immunosuppressed patients. All Authors: No reported disclosures
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
Open Access2475. Admissions Screening for Influenza and RSV Among a Highly Immunosuppressed Patient Population
During the Fall/Winter 2022-23, the U.S. experienced an early surge of Influenza and RSV cases, while SARS-CoV-2 cases persisted. With concerns of a potential “tripledemic” on the horizon, the NIH Clinical Center, a clinical research hospital with a heavily immunosuppressed patient population, implemented Influenza and RSV testing, in addition to SARS-CoV-2, for all patients on admission to facilitate early detection and prompt isolation of infected patients. Nasopharyngeal (NP) swabs (n=1213) were collected on admission from 11/2022 to 4/2023 and tested for Influenza and RSV by PCR. 1213 NP swabs from 985 unique patients were tested (some patients had multiple admissions); 1100 were tested on the Panther Fusion® SARS-CoV-2 Assay (Hologic, Inc.) and 113 using the SARS-CoV-2 RT-PCR Xpert® Xpress test. Medical chart reviews and discussions with patient care providers elucidated whether cases identified on admission were asymptomatic. Of 1213 NP swabs collected from patients admitted to our hospital, 5 (0.41%) were identified with Influenza A infection, 4 (0.33%) RSV infection and no patients were identified with Influenza B. Two (0.16%) had a known history of RSV infection, 3 (0.25%) screened negative for symptoms but subsequently disclosed symptoms, 1 (0.08%) was asymptomatic on admission but disclosed a recent history of an upper respiratory infection, and 3 were asymptomatic. All infections were detected between late November 2022 to mid-January 2023, when community transmission was high, yielding a 2-month positivity rate of 2.3% during this time of peak community spread. Admission surveillance for Influenza and RSV during a respiratory virus surge in our community allowed us to isolate nine patients on admission who would likely not have been appropriately isolated, as symptom screening alone is not reliable. Surveillance is important to be able to identify infected patients promptly when respiratory infections are rampant in the community, and especially for institutions serving immunosuppressed patients. All Authors: No reported disclosures
- 16 May 2023
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 176 (6) , 862-863
For Patient Safety, It Is Not Time to Take Off Masks in Health Care Settings
As the COVID-19 public health emergency is lifted and the pandemic continues to recede, hospitals must decide how to deescalate mitigation strategies to sustainable states. This commentary advocates continuing universal masking in health care settings.
- 16 May 2023
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 176 (6) , 862-863
For Patient Safety, It Is Not Time to Take Off Masks in Health Care Settings
As the COVID-19 public health emergency is lifted and the pandemic continues to recede, hospitals must decide how to deescalate mitigation strategies to sustainable states. This commentary advocates continuing universal masking in health care settings.
- Open Access
- 14 June 2022
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 175 (8) , 1183-1184
Adding New Fuel to the Fire: Monkeypox in the Time of COVID-19—Implications for Health Care Personnel
Monkeypox virus is reemerging, with cases reported on every inhabited continent at a time when clinical and public health resources have been stretched to the limit by COVID-19. As the monkeypox ou...
- 14 June 2022
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 175 (8) , 1183-1184
Open AccessAdding New Fuel to the Fire: Monkeypox in the Time of COVID-19—Implications for Health Care Personnel
Monkeypox virus is reemerging, with cases reported on every inhabited continent at a time when clinical and public health resources have been stretched to the limit by COVID-19. As the monkeypox ou...
- 1 December 2021
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 174 (12) , 1759-1760
Preventing Transmission of Respiratory Viruses in the Health Care Setting
In their review, Klompas and colleagues provide a scholarly assessment of the need to modify our approach to managing respiratory virus infections in health care institutions. The editorialists dis...
- 1 December 2021
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 174 (12) , 1759-1760
Preventing Transmission of Respiratory Viruses in the Health Care Setting
In their review, Klompas and colleagues provide a scholarly assessment of the need to modify our approach to managing respiratory virus infections in health care institutions. The editorialists dis...
- 2 August 2021
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 42 (10) , 1245-1250
The coronavirus disease 2019 (COVID-19) pandemic—Looking back and looking forward
- 2 August 2021
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 42 (10) , 1245-1250
The coronavirus disease 2019 (COVID-19) pandemic—Looking back and looking forward
- Open Access
- 4 September 2020
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 42 (2) , 205-207
Whither immunity? The search for effective, durable immunity to coronavirus disease 2019 (COVID-19)
- 4 September 2020
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 42 (2) , 205-207
Open AccessWhither immunity? The search for effective, durable immunity to coronavirus disease 2019 (COVID-19)
- Open Access
- 20 July 2020
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 42 (2) , 203-204
The perplexing problem of persistently PCR-positive personnel
- 20 July 2020
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 42 (2) , 203-204
Open AccessThe perplexing problem of persistently PCR-positive personnel